Detection of serum anti-p53 antibodies from patients with colorectal cancer in china using a combination of p53- and phage-ELISA: Correlation to clinical parameters

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 2921-2924

  Wu, Jing ^a   Qiu, Tian ^b   Pan, Pengtao ^a   Yu, Dehai ^a   Ju, Zhigang ^a   Qu, Xuewei ^c   Gao, Xiang ^a   Mao, Chuanbin ^c   Wang, Li ^a  

^a NORTHEAST NORMAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antibodies; Colorectal cancer; ELISA; p53; Phage display technique

Indexed keywords

EID: 84863301836     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Abdel-Aziz MM, Lotfy M, El-Kady IM, et al. (2009). Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev, 32, 329-35.
2. Atta MM, El-Masry SA, Abdel-Hameed M, et al.(2008). Value of serum anti-p53 antibodies as a prognostic factor in Egyptian patients with hepatocellular carcinoma. Clin Biochem, 41, 1131-9.
3. Angelopoulou K, Diamandis EP, Sutherland DJ, et al.(1994). Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer, 58, 480-7.
4. Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature, 351, 453-6.
5. Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, et al.(1999). Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. Pol J Pathol, 50, 77-81.
6. Crawford LV, Pim DC, Bulbrook RD (1982). Detection of antibodies against the cellular protein p53 in sera of patients with breast cancer. Int J Cancer, 30, 403-8.
7. Fujita M, Enomoto T, Murata Y (2003). Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol, 202, 97-9.
8. Gao RJ, Bao HZ, Yang Q, et al.(2005). The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation of other clinical and biological parameters. Breast Cancer Res Treat, 93, 111-5
9. Hammel P, Soussi T (2000). Serum p53 antibody assay: evaluation in colorectal cancer. Rev Med Interne, 21, 167-73.
10. Hammel P, Boissier B, Chaumette MT, et al.(1997). Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut, 40, 356-61.
11. Kressner U, Glimelius B, Bergström R, et al.(1998). Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer, 77, 1848-51.
12. Lu H, Goodell V, Disis ML (2007). Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets, 11, 235-44.
13. Lubin R, Schlichtholz B, Bengoufa D, et al.(1993). Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res, 53, 5872-76.
14. Müller M, Meyer M, Schilling T, et al.(2006). Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol, 29, 973-80.
15. Maki CG, Howley PM (1997). Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol, 17, 355-63.
16. Portefaix JM, Fanutti C, Granier C, et al.(2002). Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods, 59, 65-75.
17. Qiu T, Yang Q, Li XR, et al.(2007). Detection of serum anti-p53 antibodies from patients with ovarian cancer in China: correlation to clinical parameters. Cancer Invest, 25, 563-8.
18. Suppiah A, Alabi A, Madden L, et al.(2008). Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis, 23, 595-600.
19. Shaarawy M, Sheiba M (2004). Diagnostic and prognostic significance of circulating tumor suppressor gene p53 autoantibodies in patients with gestational trophoblastic tumors. Acta Oncol, 43, 43-8.
20. Soussi T(2000). p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res, 60, 1777-88.
21. Shiota G, Ishida M, Noguchi N, et al.(2000). Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci, 45, 122-8.
22. Yamazawa K, Shimada H, Hirai M, et al.(2007). Serum p53 antibody as a diagnostic marker of high-risk endometrial cancer. Am J Obstet Gynecol, 197, 505.e1-7.